Ayu Life Sciences Unveils AED33 Million Production Complex in the Jafza Area

Ayu Life Sciences Unveils AED33 Million Production Complex in the Jafza Area

In an exciting development for the healthcare industry, Ayu Life Sciences, a leading innovator in wound care and surgical treatments, has announced a significant investment of AED 33 million (approximately USD 8.99 million) to establish a new manufacturing plant in Dubai's Jebel Ali Free Zone (Jafza). Scheduled to be operational in phase 1 by late 2025, the facility will span 13,500 square metres and is expected to be fully completed by 2027.

The new plant will focus on producing advanced wound care and surgical treatment products, including Ayu Life Sciences' Velgraft, Velvert, and VelNez artificial-skin product lines. These innovative solutions, which include a skin substitute for scar-free healing, a wound care dressing that prevents infection, and a post-surgical nasal and ear dressing, are backed by 22 global patents and developed using eco-friendly, natural materials.

Dr. Rajan Datt, Managing Director of Ayu Life Sciences, considers this expansion a "major milestone" for the company, further emphasizing Dubai's role in advanced medical manufacturing. The strategic value of Dubai, as highlighted by Dr. Datt, lies in its ability to scale access to innovative care.

The move to Jafza underscores Dubai's growing role in advanced medical manufacturing and reinforces Jafza's position as a launchpad for global healthcare innovation. Abdulla Al Hashmi, COO of Parks & Zones at DP World GCC, expressed his excitement about this development, stating that it reinforces Jafza's position as a hub for cutting-edge healthcare solutions.

The artificial skin market is projected to grow from US$3.1 billion in 2024 to US$5.3 billion by 2032, indicating a promising future for Ayu Life Sciences' innovative products. The company currently exports to over 20 countries from its Delhi base and serves some of the world's most tightly regulated healthcare markets.

In addition to its focus on wound care solutions, Ayu Life Sciences is also researching a treatment for peripheral nerve injuries. Clinical trials for a potential Type 1 diabetes therapy are underway at the company. The expansion in Jafza is expected to contribute to innovative care access across the Middle East and beyond.

This regional first for high-tech wound care and surgical treatments in Dubai is aligned with the broader market trends where advanced wound management products hold a dominant share (64.56%) in hospitals and specialty clinics. Dubai's advanced healthcare infrastructure and regulatory environment further support the adoption of such cutting-edge technologies.

As Ayu Life Sciences continues to grow and innovate, the company is poised to make significant contributions to the global healthcare industry, particularly in the field of advanced wound care solutions.

[1] Gulf Cooperation Council (GCC) region includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. [2] Further details about the plant's operational specifics or subsequent expansion plans beyond late 2025 were not available in the provided information.

1. The healthcare industry is witnessing an exciting development as Ayu Life Sciences, a leading innovator in wound care and surgical treatments, is investing AED 33 million to establish a new manufacturing plant in Dubai's Jebel Ali Free Zone (Jafza).
2. Scheduled to be operational in phase 1 by late 2025, the facility will focus on producing advanced wound care and surgical treatment products, such as Ayu Life Sciences' Velgraft, Velvert, and VelNez artificial-skin product lines.
3. These innovative solutions, which are backed by 22 global patents and developed using eco-friendly, natural materials, are anticipated to play a significant role in the growing artificial skin market, expected to surge from US$3.1 billion in 2024 to US$5.3 billion by 2032.
4. As Ayu Life Sciences continues to grow and innovate, it also aims to extend its reach beyond wound care, pursuing research for treatments like peripheral nerve injuries and developing clinical trials for potential Type 1 diabetes therapies.
5. The strategic positioning of the new plant in Dubai highlights the city's growing role in advanced medical manufacturing and its ability to support the adoption of cutting-edge technologies in the healthcare industry.
6. Dubai's advanced healthcare infrastructure and regulatory environment further enable Ayu Life Sciences to contribute significantly to the regional healthcare market, particularly in the field of advanced wound care solutions.
7. This expansion is expected to facilitate innovative care access across the Middle East and beyond, positioning Ayu Life Sciences as a key player in the global healthcare industry.

Read also: